18/068,418 ~ GAU: 1656
`
`Attorncy Docket No.: 33320.03087.US2E/3087K
`
`IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
`
`Inventor(s)
`Serial No.
`Filed
`
`Title
`
`: Weietal.
`:
`18/068,418
`: December 19, 2022
`
`: Not yet assigned
`Art Unit
`: Not yet assigned
`Examiner
`:
`5769
`Conf. No.
`:
`13565
`Cust. No.
`- PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES
`THEREOF
`
`Mail Stop Amendment
`Commissioner for Patents
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`INFORMATION DISCLOSURE STATEMENTIN
`ACCORDANCEWITH 37 C.E.R. §§ 1.97-1.98
`
`Dear Sir:
`
`Becausethis Information Disclosure Statement is filed before the receipt of a First Office
`
`Action on the Merits for the above-captioned application, a fee is not required.If a fee forfiling
`
`these papers is required, the Commissioner1s authorized to charge the fee to Deposit Account No.
`
`50-0911.
`
`In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the
`
`Patent Office of all information known by Applicant or Applicant's representative that may be
`
`material to the examination of the subject application, Applicant's representative hereby provides
`
`this Information Disclosure Statement that is prepared in accordance with 37 C.F.R. §§ 1.97-1.98.
`
`Forms PTO-1449 (25 pages) and copies of the cited non-U.S. patent documents listed thereon are
`
`provided herewith in connection with the above-captioned application. The documentscited
`
`comprise the referencescited in the application and incorporated by reference, and any additional
`
`information of which those associated with the prosecution are aware.
`
`In accordance with 37 C.F.R. § 1.98(d), copies of the references listed on the Forms PTO-
`
`1449 that are marked with a double asterisk (**) are not provided herewith as they have been
`
`previously provided in connection with U.S. Patent Application Serial No. 13/694,731,
`
`15/226,489, 16/824,572, 17/327,568 and/or 17/327,586, whichts relied upon for an earlier filing
`
`date in accordance with 35 U.S.C. § 120.
`
`The documents cited on the Forms PTO-1449 are in the English Language with the
`
`exception of the items noted below. Item GB (CN 1020658864A)is in the Chinese Language and
`
`an English Language equivalentis listed (Item GR). Item GI (JP 2007-153797) is in the Japanese
`
`Language and an English Language Abstractis listed (Item IM). Item GJ (KR 10-2020-0017538)
`
`is in the Korean Language and an English Language equivalentis listed Item GG). Hence, in
`CERTIFICATE OF TRANSMISSIONVIA EFS-WEB
`
`Thereby certify that this paper is being transmitted via the
`
`Electronic Filing System (EFS-WEB) to the United States
`Patent and Trademark Office on March16, 2023.
`
`/Anh Nguyen /
`Anh Nguyen
`
`

`

`Inventor(s)
`Serial No.
`Filed
`
`Weiet al.
`18/068,418
`December19, 2022
`
`18/068,418 ~ GAU: 1656
`
`Attorney Docket No.: 33320.03087.US2E/3087K
`Information Disclosure Statement
`
`accordance with the requirements of 37 C.F.R. § 1.98, no further explanation of the listed items is
`
`necessary.
`
`Applicant also makes known to the Examiner the following pending U.S. Applications
`
`that have one or more commoninventors and/or an owner in common.
`
`
`
` Examiner’s|U.S.S.N.|Filing Date 3087M
`
`Publ. No.
`
`Publ. Date
`
`Docket
`Initials
`No.
`
`16/930,766|07/16/2020|2020/0368330|11/26/2020 3066D
`
`17/062,425|10/02/2020|2021/0023184|01/28/2021 3051M
`
`17/327,568|05/21/2021|2021/0284985|09/16/2021 3087E
`
`17/327,586|05/21/2021|2021/0277376|09/09/2021 3087F
`
`17/850,903|06/27/2022|2022/0372151|11/24/2022 3122B
`
`18/064,886|12/12/2022 na. n.a. 3087G
`
`
`
`18/066,960|12/15/2022 na, na. 3087H
`
`
`
`18/068,218|12/19/2022 na. n.a. 30871
`
`
`
`18/068,327|12/19/2022 na, na. 3087)
`
`
`
`18/068,443|12/19/2022 na. n.a. 3087L
`
`
`
`18/069,651|12/21/2022 na. na.
`
`
`Although these documents and applications are made known to the Patent and Trademark
`
`Office in compliance with Applicant's duty of disclosure, such disclosure is not to be construed as
`
`an admission by Applicant or Applicant's representative that any of the documents, singly or in
`
`any combination thereof, is effective as prior art against the subject application. In accordance
`
`with 37 C.ER. §§ 1.97(g) and (h),the filing of this Information Disclosure Statement shall not be
`
`construed to mean that a search has been madeor that no other material information as defined in
`
`37 CER. § 1.56(b) exists.
`
`Applicant respectfully requests that the Examiner review the foregoing documents and
`
`they be madeof record in the file history of the above-captioned application.
`
`Respectfully submitted,
`
`/Stephanie Seidman/
`Stephanie Seidman
`Reg. No. 33,779
`
`Attorney Docket No.: 33320.03087.US2E/3087K
`Addressall correspondence to: 13565
`Stephanie Seidman
`Dentons US LLP
`4655 Executive Drive, Ste. 700
`San Diego, California 92121
`Telephone:
`(619) 595-8010
`Facsimile:
`(619) 595-8135
`email: stephanie.seidman@dentons.com
`
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINER THROUGH.
`
`/C.A.M./
`
`2
`
`/CIARA A MCKNIGHT /
`
`04/19/3034
`
`